Liraglutide Effects on Memory in Healthy Subjects

University of Luebeck

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: liraglutide

Drug: Placebo

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01550653

Ott-NN-001

Details and patient eligibility

About

This study examines the hypothesis, that subcutaneous administration of liraglutide, an analogue of the incretin glucagon-like peptide 1, over 5 weeks improves memory functions in healthy humans.

Enrollment

40 patients

Sex

Male

Ages

18 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male sex
Age 18-35 years
Body mass index between 19 and 25 kg/m2
Non-smoker

Exclusion criteria

Receipt of any drug within 4 weeks prior to this trial
Any known acute or chronic disease of the brain, heart, lung, kidney,liver, pancreas or gastrointestinal tract, any metabolic, endocrine or psychiatric disease.
Brady- and Tachycardia, i.e. heart rate < 50 and > 90 beats per minute.
Hypertension (systolic blood pressure > 150 mmHg, diastolic blood pressure > 90 mmHg).
Hyperlipidemia (cholesterol, LDL, triglyceride > two times the upper reference limit based on analysis from the central laboratory)
Impaired hepatic function measured as alanine aminotransferase (ALAT) > two times the upper reference limit based on analysis from the central laboratory
Impaired renal function measured as creatinine > 120 µmol/l based on analysis from the central laboratory
Family history of diabetes
History of any eating disorder
Known or suspected allergy to trial products
History of drug or alcohol abuse within the last five years prior to screening